Navigation Links
Stem cell finding could advance immunotherapy for lung cancer
Date:11/13/2012

CINCINNATIA University of Cincinnati (UC) Cancer Institute lung cancer research team reports that lung cancer stem cells can be isolatedand then grownin a preclinical model, offering a new avenue for investigating immunotherapy treatment options that specifically target stem cells.

John C. Morris, MD, and his colleagues report their findings in the Nov. 13, 2012, issue of PLOS One, a peer-reviewed online publication that features original research from all disciplines within science and medicine.

Stem cells are unique cells that can divide and differentiate into specialized cells typesfor example cardiac muscle or liver tissue. These cells also have the ability to self-renew and produce more stem cells.

"Increasing evidence supports the idea that cancerous tumors have a population of stem cells, also called cancer-initiating cells, that continually regenerate and fuel cancer growth," explains Morris, senior author of the study and professor at the UC College of Medicine. "These cancer stem cells may also have the highest potential to spread to other organs."

Current models used to study cancer stem cells provide limited information on the interaction between cancer stem cells with the immune system, making the study of new therapies that utilize the body's immune system to fight off cancer virtually impossible.

In this study, the UC team set out to find a viable, consistent way to isolate lung cancer stem cells that could be used in a mouse model with full immune system function. The team was able to achieve this using a functional laboratory test known as "tumorsphere" assay.

The testwhich shows how cells grow in cultureallowed them to enrich for cancer stem cells.

"Studying these unique cells could greatly improve our understanding of lung cancer's origins and lead to the novel therapeutics targeting these cells and help to more effectively eradicate this disease," adds Morris. "Immunotherapy is the future of cancer treatment. We are hopeful that this new method will accelerate our investigation of immunotherapies to specifically target cancer stem cells."

The team is working to characterize how cancer stem cells escape the body's immune system in order to develop more effective therapies that target stem cells.

"One of the hypotheses behind why cancer therapies fail is that the drug only kills cells deemed to be 'bad' (because of certain molecular characteristics), but leaves behind stem cells to repopulate the tumor," adds Morris. "Stem cells are not frequently dividing, so they are much less sensitive to existing chemotherapies used to eliminate cells deemed abnormal."


'/>"/>
Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. Verinata Health Announces New Findings At The American Society Of Human Genetics
2. New findings on gene regulation and bone development
3. Finding triggers of birth defects in an embryo heart
4. One click away: Finding data on Floridas endangered species just got easier
5. New findings on protein misfolding
6. Finding new research frontiers in a single cell
7. Team discovers reason that male moths can keep finding females
8. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
9. Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science
10. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
11. UMD finding may hold key to Gaia hypothesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today that ... total of 10,672,750 common share purchase warrants have been exercised ... the exercise of these warrants totalled $1,387,458 and 10,672,750 common ... ... expression of confidence by our warrant holders. This infusion of ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
Breaking Biology Technology: